New HIV drug said to show promise

By InvestSMART · 20 Mar 2013

By InvestSMART ·
20 Mar 2013

Comments

A new way of treating HIV could be on the way, says drug developer Biotron. On Tuesday it released preliminary results of an early trial of its lead anti-viral drug, BIT225, on 21 HIV-infected patients in Thailand. "The results suggest that BIT225 is a candidate agent that could be useful in future eradication strategies," Biotron managing director Michelle Miller said.

Anti-HIV drugs target the virus in T-cells and aim to keep the virus in check and ensure the number of T-cells stays at a healthy level. But these drugs do not target "reservoirs" of HIV that exist in other cells, and which act as continuing sources of infection.

"Existing drugs clear that up [the T-cell infection], but they don't ever clear up this underlying reservoir," Dr Miller said. She said Biotron's drug worked against the underlying HIV reservoir.

Go to Google News, then click "Follow" button to add us.

Share this article and show your support

Frequently Asked Questions about this Article…

What is BIT225 and which company is developing this new HIV drug?

BIT225 is the lead anti-viral drug being developed by Biotron, a drug developer mentioned in the article.

What did Biotron announce about BIT225 in the recent early trial?

Biotron released preliminary results from an early trial showing BIT225 produced promising findings in 21 HIV-infected patients in Thailand, and the company said the results suggest BIT225 could be a candidate for future eradication strategies.

How many patients were involved in the BIT225 trial and where was it conducted?

The preliminary early trial involved 21 HIV-infected patients and was conducted in Thailand.

How does BIT225 differ from existing anti-HIV drugs?

According to Biotron, existing anti-HIV drugs target the virus in T-cells but do not clear underlying HIV “reservoirs” in other cells; Biotron says BIT225 worked against that underlying reservoir.

What are HIV 'reservoirs' and why are they important for treatment?

The article explains HIV reservoirs are virus-harbouring cells outside T-cells that act as continuing sources of infection; they matter because current drugs tend to control T-cell infection but don’t clear these reservoirs, which complicates eradication.

What did Biotron’s managing director Michelle Miller say about the significance of the results?

Michelle Miller said the results suggest BIT225 is a candidate agent that could be useful in future eradication strategies and noted that existing drugs clear T-cell infection but don’t clear the underlying reservoir—BIT225 worked against that reservoir.

Why should everyday investors pay attention to Biotron’s announcement about BIT225?

The news may be of interest because it reports preliminary positive findings for a novel HIV approach (targeting reservoirs), but the article makes clear these are early, preliminary trial results from 21 patients—information investors often weigh alongside other clinical and commercial developments.

Does the article provide a development timeline or next steps for BIT225?

No — the article only reports the preliminary results from the early trial and does not specify future trial phases, regulatory steps, or a development timeline for BIT225.